In the past two years, the epidemic has been rampant, and the entire economic situation has declined. The pharmaceutical industry has also been greatly affected. Against this challenging industry backdrop, Boliheng has maintained a good development momentum and achieved rapid and steady annual sales growth. In order to ensure production capacity, the company will invest over 7 million yuan in 2022 to build a new production line in the Wenjiang factory area, and expand, upgrade, and renovate the existing workshops to double the production capacity of the Wenjiang factory area.